Skinuvita key facts
- Provider of a home-based light therapy intended to treat skin conditions such as psoriasis and atopic dermatitis.
- It has raised $2.9M; the latest was Early Stage VC ($2.9M) in Mar 2026.
- Notable investors include High-Tech Gründerfonds, GCP Capital Partners, Die BrückenKöpfe, GIMIC Ventures, Meerkat Holding — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Skinuvita: the Monday email on marks, rounds and moves
Skinuvita funding rounds
No funding rounds for Skinuvita are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Skinuvita investors
8 investors are on record for Skinuvita, including High-Tech Gründerfonds, GCP Capital Partners, Die BrückenKöpfe and GIMIC Ventures.
About Skinuvita
Provider of a home-based light therapy intended to treat skin conditions such as psoriasis and atopic dermatitis. The company offers the ability to receive medically supervised phototherapy treatments through an app, enabling users with a non-invasive, comfortable, and privacy-conscious alternative to traditional methods, enhancing accessibility and improving the quality of life for individuals with chronic skin conditions.
- Sector
- Healthcare
- HQ
- Bremen, Germany
- Founded
- 2021
- Employees
- 17
- Website
- skinuvita.de/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Skinuvita doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.